Early Oral Anticoagulants May Be Safe for Stroke Patients with Atrial Fibrillation

A new study titled OPTIMAS suggests that starting direct oral anticoagulant (DOAC) therapy soon after an acute ischemic stroke in people with atrial fibrillation (Afib) is safe and potentially beneficial. Published in The Lancet, the trial challenges the current guidelines recommending a delay in DOAC initiation.

Key Findings of the OPTIMAS Trial

Researchers led by Dr. David Werring from University College London randomized stroke survivors to receive early or delayed DOAC initiation. Their findings demonstrated that both groups experienced similar rates of recurrent stroke, intracranial hemorrhage, or embolism at 90 days.

Here are some key takeaways from the trial:

* No difference in recurrent events: Both the early (3.3%) and delayed (3.3%) DOAC groups experienced the same rate of composite recurrent ischemic stroke, symptomatic intracranial hemorrhage, unclassifiable stroke, or systemic embolism incidence at 90 days.
* Low bleeding risk: There was a very low incidence of symptomatic intracranial hemorrhage regardless of the timing of DOAC initiation (0.6% early vs. 0.7% delayed), and the risk did not vary based on stroke severity.
* Early anticoagulation encouraged: The study concluded that early DOAC initiation is safe and does not support current guideline recommendations to delay oral anticoagulation after a stroke for up to 14 days.
* Potential for earlier treatment: The authors suggest that initiating DOAC therapy early could improve the proportion of patients who start secondary prevention treatment before hospital discharge, though further research is needed.

Addressing Current Concerns

Previous guidelines recommended delaying DOAC initiation due to concerns about the potential for early intracranial hemorrhage. However, recent research, including the OPTIMAS trial and the ELAN trial, suggests that early anticoagulation is safe and may even improve outcomes in patients with AFib after a stroke.

Study Details

OPTIMAS was a multicenter, open-label trial conducted at 100 U.K. hospitals between 2019 and 2024. It involved 3,621 patients (mean age 78.5 years, 45.3% women, 93.7% white) who were randomly assigned to early or delayed DOAC initiation.

The study authors acknowledged some limitations, including the lack of evaluation of DOAC initiation between 4 and 7 days after stroke and a limited number of participants with very severe strokes. Nevertheless, they highlighted the strengths of the study, such as the relatively broad inclusion criteria and the use of blinded endpoints.

Looking Ahead

The OPTIMAS trial provides valuable insights into the optimal timing of DOAC therapy after stroke in patients with Atrial fibrillation. Further research is needed to clarify the benefits and risks of different anticoagulation strategies based on individual patient factors.

Want to learn more about the latest stroke research and guidelines? Contact a healthcare professional or visit reputable medical websites like the American Stroke Association or the National Stroke Association.